hum0367-v1Release info

Clinical sequence of hematological malignancy

Aims

Hematopoietic malignancies such as leukemia develop as a result of the accumulation of structural and functional abnormalities in the genome and epigenome in the originating undifferentiated hematopoietic stem and progenitor cells. However, the details of the pathogenesis and the processes leading to the onset of these disorders remain unresolved, and fundamental treatments based on the pathogenic mechanisms have not been established. In this study, we aim to clarify the genomic and epigenomic abnormalities involved in the pathogenesis of hematological diseases using comprehensive genomic analysis and to search for key molecules that will lead to accurate diagnosis and drug discovery for hematological diseases based on the mechanisms.

Methods

DNAs extracted from bone marrow (BM) and lymph node (LN) samples at the time of diagnosis were subjected to a target capture sequencing analysis by using the Human Myeloid Neoplasms QIAseq Targeted DNA Panel.

Participants/materials

Langerhans cell histiocytosis (LCH)

URL

N/A

Principal investigator

Arinobu Tojo

Affiliation

Department of Hematology/Oncology, Institute of Medical Science, University of Tokyo

No research projects.

No grants.

No use of the controlled access data has been recorded.